Livagen
Patent / cell models · No established human dosing schedule
Livagen is the KEDA tetrapeptide investigated in liver-related laboratory material. Human dosing remains unestablished. Patent / cell models · No established human dosing schedule.
Reviewed 2026-10-17. A source reference, not a personal treatment plan. Discuss treatment decisions with a qualified clinician.
Dose reference
| STUDY CONTEXT | Dose | Frequency | Context |
|---|---|---|---|
| Human dosing | Not established | No validated schedule | A patent dose range is not a clinical recommendation. No human injection amount or repeated-course frequency can be derived from those experiments. Source |
A patent dose range is not a clinical recommendation. No human injection amount or repeated-course frequency can be derived from those experiments.
Source context
The inventors’ patent describes hepatocyte and animal experiments. It is a primary record of those claims, but not independent clinical validation of a liver treatment.
Reading the dose correctly
A patent dose range is not a clinical recommendation. No human injection amount or repeated-course frequency can be derived from those experiments.
Download the chart
Further reading
Livagen monograph on myPeptides
References
Why is there no numerical dose for Livagen on this card?
A patent dose range is not a clinical recommendation. No human injection amount or repeated-course frequency can be derived from those experiments.
Does a missing dose mean that no research exists?
This card describes patent / cell models. Evidence of a mechanism, a laboratory finding or an exposure does not by itself establish a useful and safe human treatment schedule. The monograph explains the distinction.